TL;DR
This study reveals that individual differences in peripheral serotonin 1B receptor (5-HT1B) gene expression can predict how acutely depleting serotonin affects risky decision-making. This suggests that readily measurable blood markers might help predict individual responses to treatments targeting the serotonin system, like SSRIs.
What Problem Does This Paper Address?
Serotonin is a key neurotransmitter implicated in decision-making, particularly in processing rewards and punishments. However, the specific serotonin receptor subtypes responsible for these effects have remained unclear. Acute Tryptophan Depletion (ATD) is a common method to temporarily lower serotonin levels in the brain, but studies on its effects on decision-making have yielded mixed results. This variability suggests that individual differences might play a crucial role in how ATD impacts behavior. The paper aims to bridge this gap by investigating whether peripheral serotonin system gene transcription levels can predict individual responses to ATD in a risky decision-making task.
Methods
The researchers employed a within-subject, double-blind, sham-controlled design with 26 participants. They used ATD to temporarily reduce serotonin levels and then had participants perform a gambling task where they chose between safer, lower-stakes gambles and riskier, higher-stakes gambles.
Key methodological aspects include:
- Acute Tryptophan Depletion (ATD): Participants consumed either a tryptophan-free amino acid drink (ATD) or a sham drink. This dietary manipulation is a standard method for transiently lowering brain serotonin synthesis.
- Peripheral mRNA Measurement: Blood samples were collected before ATD to measure the transcription levels (mRNA) of nine serotonin system genes, including various serotonin receptors (e.g., 5-HT1B, 5-HT2A) and the serotonin transporter (5-HTT). The rationale is that peripheral mRNA levels can reflect central receptor activity.
- Gambling Task: A probabilistic choice task was used to assess decision-making under risk. Participants chose between a fixed, low-reward/low-risk gamble and a variable, high-reward/high-risk gamble. The task allowed for the measurement of "sensitivity" to probability, wins, and losses.
- Computational Analysis: Beyond standard statistical analyses, the researchers used a hierarchical Bayesian mixed-effects modeling approach to gain a more detailed understanding of decision-making strategies, including parameters like probability, reward, expected value, and choice bias.
Datasets
Not discussed in the paper. The study involved human participants performing a behavioral task and providing biological samples.
Key Insights and Ideas
- Peripheral Biomarkers as Predictors: The most significant insight is that peripheral 5-HT1B mRNA levels, measured in blood, can predict how ATD affects an individual's tendency to choose riskier gambles and their sensitivity to wins. This is a crucial finding because it suggests that readily accessible biological markers could forecast responses to serotonin-modulating treatments.
- Individual Differences Matter: The study strongly supports the idea that individual differences in serotonin system gene expression are critical for understanding the effects of ATD. The inconsistent results in previous ATD studies might be explained by this variability.
- 5-HT1B Receptor's Role: The 5-HT1B receptor emerges as a key player in modulating the impact of serotonin depletion on risky decision-making, specifically influencing the choice of experimental gambles and sensitivity to wins.
- Additive Decision-Making Strategy: The computational modeling revealed that participants generally approach the gambling task using an additive strategy for probability, wins, and losses, rather than a multiplicative one predicted by standard utility theory. This suggests a simpler cognitive strategy might be at play for many individuals in this context.
Key Results
- ATD Effects: ATD did not significantly alter participants' sensitivity to probability, wins, or losses. However, there was a trend towards a reduced tendency to choose the experimental gambles overall following ATD.
- 5-HT1B Correlation: Significant positive correlations were found between baseline 5-HT1B mRNA levels and ATD-induced increases in:
- The overall tendency to choose experimental gambles (r = .658, P = .001).
-
Sensitivity to wins (r = .654, P = .001). These correlations remained significant after correction for multiple comparisons.
-
No Other Markers: No significant relationships were observed between ATD effects and the peripheral mRNA levels of other serotonin system markers tested.
- Computational Confirmation: The computational analysis confirmed the findings from the standard statistical analyses, showing a positive correlation between 5-HT1B mRNA levels and the ATD-induced increase in the "win parameter" (r = .654, P = .001).
Limitations and Future Work
- Peripheral vs. Central mRNA: The authors acknowledge that direct evidence for the relationship between peripheral and central (brain) serotonin receptor mRNA levels in humans is lacking. While studies in mice and arguments for peripheral markers as proxies exist, further validation in humans would be beneficial.
- Limited Gene Coverage: Due to low levels in blood, mRNA measurements were only reliable for nine out of twenty serotonin-related genes. Future work could explore the roles of other serotonin receptors.
- Sample Size for Correlations: The sample size for the correlational analyses (n=21) was relatively small. While the effect sizes were strong and corrected for multiple comparisons, replication with larger samples is recommended to confirm these findings.
- Future Directions: The authors suggest that future studies could investigate whether the observed correlation between 5-HT1B mRNA levels and ATD-induced changes in risky decision-making is mediated by activity changes in specific brain circuits (e.g., striatum, orbitofrontal cortex) and the serotonin or dopamine systems. They also highlight the potential utility of peripheral serotonin markers for predicting individual responses to clinical treatments targeting the serotonin system, such as SSRIs.
Summary updated